Evidence map›Paper›PMID 27667667›Full record

ArticleCell metabolism2016

Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes.

Åsa Segerstolpe, Athanasia Palasantza, Pernilla Eliasson, Eva-Marie Andersson, Anne-Christine Andréasson, Xiaoyan Sun, Simone Picelli, Alan Sabirsh, Maryam Clausen, Magnus K Bjursell and 4 more

Registry-linked trialAbstract read
In one paragraph

Article in Cell metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04432090 (A Randomized, Placebo-controlled, Double-blinded Cross-over Study of the Pharmacologic Action of a GPR119 Agonist on Glucagon Counter-regulation During Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus), which is not on this map. Cited by 911 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
911citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04432090 phase2completednot on this mapstarted 2021, after this paper: background citation

A Randomized, Placebo-controlled, Double-blinded Cross-over Study of the Pharmacologic Action of a GPR119 Agonist on Glucagon Counter-regulation During Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus

TypeinterventionalSponsorAdventHealth Translational Research InstituteRan2021 to 2023Enrolled110ConditionsDiabetes Mellitus, Type 1ArmsPlacebo, Study Medication (MBX-2982), No medication for this group
3 · Its place in the literature

Who cites it

911 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Interpretable scRNA-seq Analysis with Intelligent Gene Selection.Applied biochemistry and biotechnology · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Reevaluating the role of TRPV6 deficiency in human and mouse pancreatitis.American journal of physiology. Gastrointestinal and liver physiology · 2026
    Article
  20. Article

851 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Åsa SegerstolpeDepartment of Cell and Molecular Biology (CMB), Karolinska Institutet, 171 77 Stockholm, Sweden; Integrated Cardio Metabolic Center (ICMC), Karolinska Institutet, 141 57 Huddinge, Sweden.
Athanasia PalasantzaDepartment of Cell and Molecular Biology (CMB), Karolinska Institutet, 171 77 Stockholm, Sweden.
Pernilla EliassonCardiovascular and Metabolic Diseases (CVMD), Innovative Medicines and Early Development Biotech Unit (iMed), AstraZeneca, 431 83 Mölndal, Sweden.
Eva-Marie AnderssonCardiovascular and Metabolic Diseases (CVMD), Innovative Medicines and Early Development Biotech Unit (iMed), AstraZeneca, 431 83 Mölndal, Sweden.
Anne-Christine AndréassonCardiovascular and Metabolic Diseases (CVMD), Innovative Medicines and Early Development Biotech Unit (iMed), AstraZeneca, 431 83 Mölndal, Sweden.
Xiaoyan SunDepartment of Biosciences and Nutrition and Center for Innovative Medicine, Novum, Karolinska Institutet, 141 83 Huddinge, Sweden.
Simone PicelliLudwig Institute for Cancer Research, 171 77 Stockholm, Sweden.
Alan SabirshCardiovascular and Metabolic Diseases (CVMD), Innovative Medicines and Early Development Biotech Unit (iMed), AstraZeneca, 431 83 Mölndal, Sweden.
Maryam ClausenDiscovery Sciences, Innovative Medicines and Early Development Biotech Unit (iMed), AstraZeneca, 431 83 Mölndal, Sweden.
Magnus K BjursellR&D Information (RDI), AstraZeneca, 431 83 Mölndal, Sweden.
David M SmithDiscovery Sciences, Innovative Medicines and Early Development Biotech Unit (iMed), AstraZeneca, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, UK.
Maria KasperDepartment of Biosciences and Nutrition and Center for Innovative Medicine, Novum, Karolinska Institutet, 141 83 Huddinge, Sweden.
Carina ÄmmäläCardiovascular and Metabolic Diseases (CVMD), Innovative Medicines and Early Development Biotech Unit (iMed), AstraZeneca, 431 83 Mölndal, Sweden.
Rickard SandbergDepartment of Cell and Molecular Biology (CMB), Karolinska Institutet, 171 77 Stockholm, Sweden; Integrated Cardio Metabolic Center (ICMC), Karolinska Institutet, 141 57 Huddinge, Sweden; Ludwig Institute for Cancer Research, 171 77 Stockholm, Sweden. Electronic address: rickard.sandberg@ki.se.

Funding

European Research Council 648842
6 · The paper itself

Abstract

Hormone-secreting cells within pancreatic islets of Langerhans play important roles in metabolic homeostasis and disease. However, their transcriptional characterization is still incomplete. Here, we sequenced the transcriptomes of thousands of human islet cells from healthy and type 2 diabetic donors. We could define specific genetic programs for each individual endocrine and exocrine cell type, even for rare δ, γ, ε, and stellate cells, and revealed subpopulations of α, β, and acinar cells. Intriguingly, δ cells expressed several important receptors, indicating an unrecognized importance of these cells in integrating paracrine and systemic metabolic signals. Genes previously associated with obesity or diabetes were found to correlate with BMI. Finally, comparing healthy and T2D transcriptomes in a cell-type resolved manner uncovered candidates for future functional studies. Altogether, our analyses demonstrate the utility of the generated single-cell gene expression resource.

Indexed as

Diabetes Mellitus, Type 2Gene Expression ProfilingGlucagon-Like Peptide-1 ReceptorHumansIslets of LangerhansMaleObesityReproducibility of ResultsSingle-Cell AnalysisTissue DonorsTranscription FactorsGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorTranscription Factors

Identifiers

PMID27667667
PMCPMC5069352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.